Cor.Sync

Cor.Sync, founded in 2019 and headquartered in São Paulo, Brazil, is a medical technology company developing a point-of-care platform for the rapid diagnosis of myocardial infarction. The company was co-founded by Raul de Macedo (CEO), Paulo Garcia (CTO), Alexandre Costa, and Dr. Attílio Galhardo. The inspiration for the company came from CEO Raul de Macedo's personal experience in 2016 when he faced a lengthy wait for a diagnosis after being admitted to an emergency room with chest pains. This event motivated him, from an engineering perspective, to develop a faster diagnostic solution for such a critical and often fatal condition.

The core of Cor.Sync's solution is a benchtop device that uses patented technology with high-specificity sensors to measure cardiac troponin levels from a whole blood sample in just eight minutes, a significant reduction from the one to five hours required for traditional lab tests. The technology utilizes surface plasmon resonance (SPR) and does not require sample preparation, making it practical for triage and emergency environments. This device is complemented by a clinical decision support software platform that integrates the test results with the patient's electronic health records. Using artificial intelligence and machine learning algorithms, the software provides diagnostic probability, risk of mortality, and treatment recommendations to aid healthcare professionals in making evidence-based clinical decisions.

The company targets hospitals, laboratories, and healthcare systems, aiming to improve patient outcomes and reduce healthcare costs by enabling quicker and more accurate diagnoses. The business model involves the combination of the point-of-care device and single-use biosensors. Cor.Sync has received support and funding from various entities, including FAPESP's Innovative Research in Small Businesses Program (PIPE), and has gained international recognition at events like VivaTech in Paris. Investors include Bossa Invest, DOMO.VC, and Biominas Brasil. While currently focused on cardiac diagnosis, the company's patented method is a platform technology with a roadmap to develop tests for other biomarkers in fields such as oncology and infectology.

Keywords: point-of-care diagnostics, cardiac troponin testing, myocardial infarction diagnosis, medical device, HealthTech, AI in healthcare, clinical decision support, biosensors, surface plasmon resonance, emergency medicine, cardiovascular diagnostics, diagnostic equipment, fast medical diagnosis, in-vitro diagnostics, Raul de Macedo, Paulo Garcia, digital health, FAPESP, VivaTech, DOMO.VC